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The usefulness of many p-lactams, including the third-generation cephalosporins, has been threatened in recent years 
by the dissemination of P-lactamase-mediated resistance. The carbapenems, meropenem and imipenem/cilastatin, 
demonstrate ultra-broad spectra of antibacterial activity which encompass the majority of clinically significant Gram- 
positive and Gram-negative aerobic and anaerobic pathogens. Due to  the unique arrangement of the moieties arocind 
the carbapenem p-lactam ring, these agents possess unrivaled stability t o  almost all serine p-lactamases, including the 
mutant extended-spectrum types produced by Enterobacteriaceae which hydrolyze third-generation cephalosporins. 
Meropenem has a number of additional structural features which confer advantages over imipenem, notably stability 
t o  metabolism by dehydropeptidase-l and enhanced activity against Gram-negative organisms, including Pseudornonas 
aeruginosa. 
In the treatment of nosocomial respiratory tract infections, meropenem monotherapy has compared favorably with 
ceftazidime plus aminoglycoside combination regimens or imipenem/cilastatin, producing rates of clinical efficacy of 
>75%. Likewise, in patients with intra-abdominal infections, meropenem has proved to  be as efficacious as clindamycin 
plus tobramycin, cefotaxime plus metronidazole and equivalent dosages of imipenem/cilastatin. Meropenem is well 
tolerated by the central nervous system and, unlike imipenem/cilastatin, is approved for the treatment of meningitis. 
Key words: Carbapenems, p-lactamase, drug resistance, meropenem 
INTRODUCTION 
During the last 20 years, a succession of new antibiotics 
have been developed to counter the emergence of 
resistance to older agents. In the early 1980s, third- 
generation cephalosporins such as cefotaxime were 
introduced. Initially these agents had enhanced stability 
to (3-lactamases produced by Enterobacteriaceae, but 
the recent emergence of mutant extended-spectrum 
(3-lactamases (ESBLs) has threatened the utility of these 
agents as empiric therapy in many areas of the world. 
This review discusses the advantages of the carbapenem 
class of antibiotics. 
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DEVELOPMENT OF CARBAPENEMS 
Carbapenem compounds were first dscovered in 1976 
[1,2]. Thienamycin, isolated from Streptomycer cuttleyu, 
appeared to be the most promising of these early 
compounds. However, the usefulness of thienamycin 
was limited by its inherent concentration-dependent 
chemical instability [2]. 
In 1979, the stable derivative N-formimidoyl- 
thienamycin, or imipenem, was developed. This com- 
pound is extensively hydrolyzed by dehydropeptidase- 
I (DHP-I) in the brush border of the renal tubule [3], 
with two important consequences [4,5]. First, the 
penetration of imipenem into the urine may be 
insufficient for the treatment of urinary tract infections. 
Second, high dosages of imipenem induce proximal 
tubular necrosis in laboratory animals. These problems 
were overcome by the discovery of cilastatin, a reversible 
competitive inhibitor of DHP-I. Co-administration of 
cilastatin (in a 1 : 1 ratio) increases urinary recovery of 
imipenem to approximately 60-70% and prevents the 
aforementioned nephrotoxicity [3].  
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Meropenem, developed during the 1980s, repre- 
sents a further advance in the structural chemistry of 
the carbapenems. The meropenem molecule possesses 
a 1 P-methyl substitution which provides relative stability 
to DHP-I [6]. Almost 70% of a dose of meropenem is 
recovered intact in the urine within 12 h of admini- 
stration, and co-administration of a DHP-I inhibitor is 
not required [7,8]. 
STRUCTURE-ACTIVITY RELATIONSHIPS 
The five-membered thiazolidine ring of the carba- 
penems differs from that of penicillins in having a 
carbon atom (instead of a sulfur atom) at position 1 and 
an unsaturated bond between the carbon atoms at 
positions 2 and 3 (Figure 1). In addition, the carba- 
penems have a hydroxyethyl side-chain on the p-lactam 
ring, whereas penicillins and cephalosporins have an 
acylamino substituent in this position. The relatively 
small hydroxyethyl side-chain in the carbapenem 
molecule, in combination with the zwitterionic charge 
state, allows both imipenem and meropenem to pass 
freely through the porin channels in the outer mem- 
branes of Gram-negative bacteria [9,10]. 
P-Lactamase stability 
In many species of Gram-negative bacteria, antibiotics 
which have reached the periplasm face attack by 
P-lactamases. Importantly, the hydrogen atoms at 
positions 5 and 6 in the P-lactam ring of carbapenems, 
unlike those in other p-lactams, are arranged in a trans 
configuration (i.e. on opposite sides of the ring). The 
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Figure 1 Chemical structure of meropenem. 1, Hydroxy- 
ethyl moiety in trans configuration confers stabhty to 
serine p-lactamases. 2, p-lactam ring provides high af5nity 
for penicillin-binding proteins. 3, Carbapenem nucleus 
associated with ultra-broad antibacterial spectrum. 4, C1 
methyl group improves stability to renal dehydropeptidase-I. 
5, C2 moiety enhances activity against Gram-negative 
pathogens, including Pseudomonas aeruginosa, and may also 
account for the good central nervous system tolerability of 
meropenem. 
hydroxyethyl side-chain is forced 6 to the ring, which 
stabilizes the molecule to hydrolysis by almost all serine 
P-lactaniases, including mutant TEM- and SHV-type 
ESBLs. 
There are isolated reports of serine P-lactamases 
produced by Enterobacteriaceae which are capable of 
hydrolyzing carbapenems [11,12], but these enzymes 
are rare and not easily transferable [13]. Interestingly, 
one report has described strains of carbapenemase- 
producing Sevratia which were resistant to imipenem 
(MIC 16 mg/L) but susceptible to meropenem (MIC 
0.12 mg/L) [12]. The carbapenems are susceptible to 
hydrolysis by zinc-dependent P-lactamases produced 
by Stenotrophomonas maltophilia and some strains of 
Aeromonas [14]. Reports from Japan have described 
a plasmid-borne zinc-dependent carbapenemase in 
Pseudomonas aeruginosu [15,16]. 
Penicillin-binding protein affinity 
Carbapenems, like other P-lactams, kill bacteria by 
binding to penicillin-binding proteins (PBPs) on the 
cytoplasmic membrane, thereby inhibiting peptido- 
glycan (cell wall) biosynthesis. Several types of PBPs 
have been identified and the affinity shown by the 
carbapenems for each has been studied in certain 
bacteria (Table 1). Overall, the carbapenems have hlgh 
affinities for the essential PBPs and one would expect 
these targets to be saturated using the recommended 
dosage schedules. 
Imipenem and meropenem bind to all four PBPs 
identified in Staphylococcus aureus, although meropenem 
has a relatively low affinity for PBP3 [17]. In Escherichia 
coli, both meropenem and imipenem bind with highest 
affinity to PBP2 and PBP4 [10,18]. Analysis of the 
morphologic changes induced by these agents indicates 
that PBP2 is the primary target in this organism [19]. 
The two carbapenems differ in their PBP-binding 
profiles in l? aeruginosa. Imipenem binds with high 
affinity to PBP2, PBPS and PBP4, with PBP2 being 
the primary target [19]. Meropenem has a higher 
affinity than imipenem for PBP2 and PBPS but the 
latter is the primary target for this agent [18]. 
Antibacterial spectra 
The carbapenems possess the broadest antibacterial 
spectra of any class of antibiotics. They are active against 
almost all clinically important Gram-positive and 
Gram-negative aerobic and anaerobic pathogens, with 
the exceptions of methicillin-resistant staphylococci, 
Enterococrus faecium and Stenotrophomonar maltophilia [20]. 
Imipenem is more active than meropenem against 
some Gram-positive cocci (mainly staphylococci), 
while meropenem is the more active agent against 
Enterobacteriaceae, l? aeruginosa and certain other 
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Table 1 Penicillin-binding protein (PBP) profiles of meropenem and imipenem 
Isod for PBPs 
Organism Drug 1 2 3 4 - - MIC (mdL) 
Staphylococcus aureusa Meropenem 0.064 0.45 >I00 0.053 - - 0.05 
Imipenem 0.033 0.17 0.12 0.0092 - - 0.013 
l a  l b  2 3 4 5 6 
Escherirhia coli" Meropenem 0.82 0.58 0.011 0.72 0.04 2.4 22 0.015 
Imipenem 0.18 0.81 0.031 17.3 0.02 0.9 4.3 0.06 
- Pseudomonas Meropenem' 0.14 0.06 0.025 0.01 0.2 >11 0.5 
aeruginosa Imipenem' 0.08 0.22 0.06 0.06 0.08 0.12 - 2 
Meropenem' 0.27 0.24 0.03 0.031 0.010 15 - 0.05 
Imipenem' 0.15 0.46 0.11 0.28 0.011 1.8 - 0.78 
'Data from Sumita et al [17]; 'Data from Kitzis et al [18]; 'Data from Sumita et a l  [19]; dConcentration of competitor (mg/L) giving 50% 
inhibition of binding of radiolabeled benzylpenicdhn. 
Gram-negative pathogens. This enhanced activity 
against Gram-negative bacteria is due to the dimethyl- 
carbonylpyrrolidinethio side-chain in the C2 position 
in the meropenem molecule [21]. 
As already stated, the potent activity of the carba- 
penems is coupled with exceptional stability to serine 
p-lactamases. Table 2 demonstrates that MICs of the 
carbapenems, unlike those of comparators, are not 
significantly increased in Gram-negative bacteria with 
derepressed production of class C p-lactamases com- 
pared with parent strains. MICs of third-generation 
cephalosporins, in particular ceftazidime, against Entero- 
bacteriaceae are raised considerably in the presence of 
mutant plasmid-mediated ESBLs such as the TEM- 
derived enzymes (Table 2) [20]. The fourth-generation 
cephalosporins cefpirome and cefepime show only a 
modest (2-4-fold) improvement over cefotaxime and 
ceftriaxone in this regard. Moreover, the MICs of 
these fourth-generation agents may be elevated further 
against large inocula or strains in which (3-lactamase 
production is increased by promoter sequences. In 
contrast, the carbapenems remain highly active against 
strains which produce ESBLs, with meropenem being 
the more potent agent. 
The antibacterial activity of meropenem, like that 
of all (3-lactams, is dependent on the time for which its 
concentration exceeds the MIC of the target pathogen, 
rather than on the peak concentration it achieves or 
the area under the plasma concentration-time curve 
(AUC)/MIC [22]. Studies in animals have indicated 
that meropenem inhibits the growth of Gram-negative 
bacteria when its concentration exceeds the MIC for 
only 20-30% of the dosing interval [23]. In contrast, 
against these organisms the concentration of third- 
generation cephalosporins must remain above the MIC 
for 35-55% of the dosing interval for a bacteriostatic 
effect to occur [24]. Pharmacokinetic and in vitro 
bacterial susceptibility data indicate that the mero- 
penem plasma concentration following a dosage of 1 g 
8-hourly exceeds the MICs of virtually all clinically 
important pathogens for over 40% of the dosage interval 
which provides maximal bactericidal activity. 
CLINICAL EXPERIENCE WITH MEROPENEM 
Meropenem has been evaluated in an extensive clinical 
trial program in patients with a variety of infections 
[25,26], includmg lower respiratory tract infections 
(LRTIs) [27,28], intra-abdominal [29-341, skidskin 
structure [35], urinary tract [36], and obstetric/ 
gynecologic infections [37], septicemia 1381, meningitis 
[39,40] and neutropenia 1411. Studies have also been 
performed specifically in pediatric patients [42]. Data 
obtained with the drug in the treatment of three 
important types of infection, namely nosocomial 
LRTIs, intra-abdominal infection and meningitis, are 
reviewed here. 
Nosocomial LRTI 
Nosocomial pneumonia is the second most common 
nosocomial infection [43]. The mortality rate associ- 
ated with nosocomial pneumonia, higher than those 
from other nosocomial infections, is approximately 
30% [44] but may be even higher in patients who 
are bacteremic, artificially ventilated or infected with 
l? aeruginosa or Acinetobacter spp. 143,451. 
Traditionally, combinations of antibiotics have been 
used to achieve the broad spectrum of activity necessary 
in the empirical treatment of nosocomial LRTI. 
However, the ultra-broad spectrum of the carbapenems 
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permits the use of these agents as monotherapy and, 
indeed, meropenem has proved to be as efficacious as 
combination therapy in this setting (Figure 2). In 
one study, meropenem (1 g three times daily) was as 
effective as ceftazidime (2 g three times daily) plus 
amikacin (15 mg/kg per day) in the treatment of a 
variety of serious nosocomial infections, including 
LRTIs [25]. In patients with serious hospital-acquired 
LRTIs, the clinical success rate at the end of treatment 
with meropenem was 30 of 37 (81%), compared 
with 23 of 32 (72%) with ceftazidime/amikacin. The 
bacteriologic success rates were similar with the two 
regimens (71% versus 76%). In another study in a total 
of 121 evaluable patients with hospital-acquired LRTIs, 
meropenem (1 g 8-hourly) produced significantly 
higher rates of clinical success (89% versus 72%, 
p=O.04) and bacteriologic success (89% versus 67%, 
p=0.006) than ceftazidime (2 g 8-hourly) plus tobra- 
mycin (1 mg/kg 8-hourly) [28]. 
A recent study compared meropenem and imi- 
penem/cilastatin (both 1 g 8-hourly) as empiric 
monotherapy in the treatment of critically ill patients 
(mean APACHE I1 scores 14.9 versus 14.4) with serious 
bacterial infections [26]. Eighty of 204 (39%) patients 
in this study had nosocomial LRTIs. At the end 
of treatment, meropenem and imipenem/cilastatin 
achieved similar rates of satisfactory clinical (75% versus 
75%) and bacteriologic (48% versus 52%) response in 
these patients. 
Intra-abdominal infection 
Antibiotic regimens suitable for the treatment of intra- 
abdominal infections must be active against Entero- 
bacteriaceae and anaerobes (particularly Burteroides 
fvagilis) [46]. A variety of combination regimens have 
been employed for this purpose, but since the carba- 
penems are active against both aerobic and anaerobic 
pathogens, these agents offer the opportunity for 
empiric monotherapy. 
Prospective randomized comparative studies have 
shown meropenem (1 g 8-hourly) to be as efficacious 
in the treatment of serious intra-abdominal infections 
as cefotaxime (2 g 8-hourly) plus metronidazole 
(500 mg 8-hourly) [29] or clindamycin (0.9 g 8-hourly) 
plus tobramycin (5 mg/kg per day) [30] (Figure 3). 
In these studies, the rates of clinical success and 
bacteriologic eradication with meropenem were 
91-92% and 90-93%, respectively. 
Two trials compared meropenem and imipenem/ 
cilastatin, using both agents at a dosage of 1 g 8-hourly, 
in the management of serious intra-abdominal infect- 
ions [32,33]. The two drugs produced similar rates of 
clinical (96-100% versus 94-97%) and bacteriologic 
(84-90% versus 81-100%) success at the end of 
Drusano:  M e r o p e n e m :  l a b o r a t o r y  and  c l in ica l  da ta  4 s 5 5  
treatment. Another study, performed mainly in patients 
with appendicitis, compared meropenem and imi- 
penem/cilastatin a t  a lower dosage (0.5 g 8-hourly) 
[34]. Again, the drugs demonstrated similar clinical and 
bacteriologic success rates in excess of 95%. 
An aforementioned study comparing meropenem 
and imipenem/cilastatin (both 1 g 8-hourly) in critically 
ill patients with a variety of infections, reported that the 
two antibiotics produced similar rates of satisfactory 
clinical response in patients with intra-abdominal in- 
fections (82% versus 81%, respectively) [31]. In those 
patients with polymicrobial intra-abdominal infections, 
the satisfactory clinical success rate with meropenem 
was 80%, compared to 70% with imipenem/cilastatin. 
Overall, both drugs achieved similar bacteriologic 
response rates of 68-70%. 
Meningitis 
Meropenem penetrates into the cerebrospinal fluid in 
patients with meningitis [47]. The drug is highly active 
against common pathogens responsible for meningitis 
in adults and children, including Styelltococcus pneumoniae, 
Haemophilus influenzae and Neisseria meningitidis [48]. 
Importantly, meropenem is active in vitro against 
penicillin- and cephalosporin-resistant Streptococcus pneu- 
moniae [48]. Resistance to p-lactams in this organism is 
caused by alteration of PBP structure, rather than by 
6-lactamase production [49]. During the last 20 years, 
resistant strains have spread throughout the world; at  
present, countries in which the incidence is particularly 
high (>20%) include Spain [SO], Hungary [Sl], South 
Africa [52] and certain areas of the USA [53,54]. 
In recent years cefotaxime and ceftriaxone have 
been regarded as first-line options in the empiric 
treatment of pneumococcal meningitis, including that 
caused by relatively penicillin-resistant strains. How- 
ever, strains of pneumococci with resistance to these 
agents have been observed and treatment failures follow- 
ing their use as empiric therapy have been reported 
[55-571. 
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Figure 2 Comparative efficacy of meropenem and combination regimens in two separate studies in patients with 
nosocomial lower respiratory tract infections. Dosages: amikacin 15 mg/kg once daily; meropenem 1 g %hourly; ceftazihme 
2 g %hourly; tobramycin 1 mg/kg %hourly. n=number of patients evaulated. *p=0.04 versus cefiazidime + tobramycin; 
**p=0.006 versus ceftazidime + tobramycin. 
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Figure 3 Eficacy of meropenem and comparators in patients with intra-abdominal infections. CTX, cefotaxime; 
CLI, clindamycin; IPM/C; imipenem/chstatin; MEM, meropenem; MTR, metronidazole; TOB, tobramycin; n = number 
of patients evaluated. 
Although imipenem/cilastatin has a similar spec- 
trum of activity, it is not indicated for the treatment 
of meningitis because it has been associated with a 
relatively high risk of seizures in this patient group. 
Overall, the incidence of drug-related seizures with 
imipenem/cilastatin has been reported to be 0.9% [58]. 
However, the risk of seizures is increased in patients 
with certain risk factors, such as pre-existing central 
nervous system disorders and renal impairment. A study 
with imipenem/cilastatin in chldren with meningitis 
was terminated when seizures were reported in 7 of 
21 (33%) patients [59]. In contrast, meropenem has 
demonstrated a relatively low propensity to induce 
seizures in animal models 160-631 and clinical studies 
in children and adults [64]. 
In comparative clinical studies involving a total 
of 246 patients with meningitis, meropenem (up to 
6g/day in adults and 120 mg/kg daily in children) 
proved as efficacious as cefotaxime (225-300 mg/kg 
daily up to a maximum of 12 g/day) or cefiriaxone (100 
mg/kg initial dose, followed by a single dady dose of 
80 mg/kg up to a maximum of 4g/day) [39,40]. 
Dexamethasone was administered concurrently to 91 % 
of patients in these studies. Meropenem produced 
clinical cure and bacteriologic eradication in 100% of 
evaluable adult and pediatric patients. Importantly, 
there were no significant differences between mero- 
penem and comparator antibiotics with respect to 
central nervous system tolerability. Indeed, there have 
been no seizures attributed to drug therapy in trials 
performed to date with meropenem in pediatric 
patients with meningitis [64]. 
CONCLUSION 
The carbapenems possess several advantageous pro- 
perties, including rapid penetration of Gram-negative 
bacterial cells, high PBP affinities, unrivaled anti- 
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bacterial spectra and exceptional (3-lactamase stability. 
These properties would seem to be increasingly im- 
portant as the development of resistance, particularly 
that mediated by 6-lactamases, has compromized the 
usefulness of many other (3-lactams. Meropenem, a 
new carbapenem, has proved as eficacious as combina- 
tion regimens and other monotherapy options in the 
treatment of serious infections such as nosocomial 
LRTIs and intra-abdominal infections. Importantly, 
meropenem is well tolerated by the central nervous 
system and is the only carbapenem currently approved 
outside Japan for the treatment of meningitis. 
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